Copyright © 2025 MarketWatch, Inc. All rights reserved.

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

New York, New York--(Newsfile Corp. - March 22, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) ...

7th Apr 2025 7:00 am RNS Transaction in Own Shares 4th Apr 2025 7:00 am RNS Transaction in Own Shares 3rd Apr 2025 7:00 am RNS Transaction in Own Shares 2nd Apr 2025 7:00 am RNS Transaction in Own ...

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related ...